Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

319

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia

Interventions

DRUG: Vadadustat
DRUG: Darbepoetin alfa

Sponsor

Akebia Therapeutics

Collaborators

[object Object]